Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer.

By Xin-long Liu, J. Deng, Yang Yuan, Wujun Chen, Wenshe Sun, Yanhong Wang, Haiming Huang, B. Liang, Tao Ming, Jialian Wen and 2 more. 2022

Subfields: Oncology, Pharmacology

Citations in the corpus

• TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome (2026, unknown): “…that persist across disease stages are essential for the effective development of antibody-based therapies, including monoclonal antibodies and antibody – drug conjugates (ADCs) as it is already an important therapeutic target in various solid tumors as lung cancer and breast cancer (17, 36 – 38).”